Stephens Inc. AR Boosts Holdings in Humana Inc. (NYSE:HUM)

Stephens Inc. AR increased its holdings in Humana Inc. (NYSE:HUMFree Report) by 23.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,606 shares of the insurance provider’s stock after purchasing an additional 679 shares during the period. Stephens Inc. AR’s holdings in Humana were worth $1,651,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HUM. Morgan Stanley boosted its stake in shares of Humana by 6.2% during the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after purchasing an additional 119,760 shares during the period. Ameriprise Financial Inc. boosted its position in Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after buying an additional 402,559 shares during the period. Norges Bank purchased a new position in shares of Humana in the fourth quarter valued at about $676,800,000. Northern Trust Corp raised its stake in shares of Humana by 5.1% during the third quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after acquiring an additional 64,245 shares during the last quarter. Finally, Sanders Capital LLC bought a new position in shares of Humana during the fourth quarter valued at about $489,300,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of Humana stock opened at $351.80 on Monday. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm’s 50-day moving average is $332.50 and its 200 day moving average is $361.86. The stock has a market cap of $42.39 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 2.07 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67.

Humana (NYSE:HUMGet Free Report) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $9.38 earnings per share. Sell-side analysts anticipate that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Analyst Ratings Changes

A number of brokerages recently issued reports on HUM. Bank of America boosted their price target on Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. The Goldman Sachs Group dropped their price target on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. TD Cowen reduced their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Oppenheimer dropped their target price on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Finally, Cantor Fitzgerald reduced their price target on shares of Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $423.63.

Check Out Our Latest Stock Analysis on Humana

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.